Outlook Therapeutics, Inc. financial data

Symbol
OTLK on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
111 S. Wood Avenue, Unit #100, Iselin, NJ
State of incorporation
DE
Fiscal year end
September 30
Former names
Oncobiologics, Inc. (to 11/13/2018)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 81.7 % -43.4%
Debt-to-equity -162 % -130%
Return On Equity 147 %
Return On Assets -235 % -84.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 23.7M shares -90.9%
Common Stock, Shares, Outstanding 23.4M shares -91%
Entity Public Float 180M USD -19%
Common Stock, Value, Issued 234K USD -91%
Weighted Average Number of Shares Outstanding, Basic 23.2M shares +80.8%
Weighted Average Number of Shares Outstanding, Diluted 25.5M shares +98.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 34.2M USD +12.1%
General and Administrative Expense 27.1M USD +12.2%
Operating Income (Loss) -61.3M USD -12.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 44.4M USD
Income Tax Expense (Benefit) 2.8K USD 0%
Net Income (Loss) Attributable to Parent -94M USD -55.9%
Earnings Per Share, Basic -4.17 USD/shares -83.7%
Earnings Per Share, Diluted -6.97 USD/shares -207%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 32M USD -5%
Assets, Current 45.6M USD +6.04%
Property, Plant and Equipment, Net 40.9K USD -80%
Operating Lease, Right-of-Use Asset 286K USD +666%
Other Assets, Noncurrent 479K USD -18.7%
Assets 47.1M USD +5.95%
Accounts Payable, Current 5.55M USD +9.83%
Employee-related Liabilities, Current 895K USD -54.2%
Accrued Liabilities, Current 2.68M USD -67.6%
Liabilities, Current 42.6M USD -14.8%
Operating Lease, Liability, Noncurrent 260K USD
Liabilities 131M USD +162%
Retained Earnings (Accumulated Deficit) -549M USD -20.7%
Stockholders' Equity Attributable to Parent -83.7M USD -1421%
Liabilities and Equity 47.1M USD +5.95%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13M USD -46.4%
Net Cash Provided by (Used in) Financing Activities 43.8M USD -34.2%
Common Stock, Shares Authorized 60M shares -85.9%
Common Stock, Shares, Issued 23.4M shares -91%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -13M USD -137%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 32M USD -5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.16M USD +5650%
Deferred Tax Assets, Valuation Allowance 120M USD +16.7%
Deferred Tax Assets, Gross 120M USD +16.6%
Operating Lease, Liability 292K USD
Depreciation 164K USD +0%
Lessee, Operating Lease, Liability, to be Paid 375K USD
Property, Plant and Equipment, Gross 1.07M USD 0%
Operating Lease, Liability, Current 31.8K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 80K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 78.1K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +26.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 82.4K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 81.8K USD
Deferred Tax Assets, Operating Loss Carryforwards 93M USD +10.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares +37%
Unrecognized Tax Benefits 1.86M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 83.7K USD
Operating Lease, Payments 11.9K USD +2.94%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 7.36K USD -62.8%
Share-based Payment Arrangement, Expense 5.37M USD -2.98%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%